Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F14%3A00080066" target="_blank" >RIV/00216224:14110/14:00080066 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002" target="_blank" >http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3978/j.issn.2218-6751.2014.AB002" target="_blank" >10.3978/j.issn.2218-6751.2014.AB002</a>
Alternative languages
Result language
angličtina
Original language name
Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Original language description
Background: Worldwide, lung cancer is the most common cause of cancer-related death, and was responsible for 1.56 million deaths annually, as of 2012. The situation in the Czech Republic is identical, lung cancer is the leading cause of mortality due tomalignant tumours, with 5,572 cancer related deaths in 2010. The detection of epidermal growth factor receptor (EGFR) gene mutations can guide targeted therapies for non-small cell lung cancer (NSCLC), because most of these mutations are strongly associated with clinical response to EGFR tyrosine kinase inhibitors. The aim of this study was to verify the frequency of EGFR mutations in a large group of Caucasians patients with advanced stage non-squamous NSCLC. Methods: Analysed data were collected in the period from November 15, 2011 to June 30, 2013 in three pneumo-oncological centres.
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
FC - Pneumology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů